|
Real-time Estimate
Cboe BZX
12:09:14 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 7.000 USD | -3.98% |
|
-27.46% | -42.34% |
| 15/09 | Ocular Therapeutix, Inc. Completes Pre-NDA Meeting With FDA For AXPAXLI In Wet AMD | CI |
| 15/09 | Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4 | MT |
| Market Cap | 160.1Cr 142.25Cr 132.77Cr 121.01Cr 228.23Cr 15TCr 230.35Cr 1.61TCr 622.6Cr 7.87TCr 601.1Cr 588.05Cr 25TCr | P/E 2026 * |
-4.89x | P/E 2027 * | -5.23x |
|---|---|---|---|---|---|
| Enterprise Value | 122.3Cr 108.66Cr 101.42Cr 92Cr 174.34Cr 12TCr 175.97Cr 1.23TCr 475.6Cr 6.01TCr 459.18Cr 449.21Cr 19TCr | EV / Sales 2026 * |
23.1x | EV / Sales 2027 * | 15x |
| Free-Float |
99.07% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| OCUL | Delayed | |
CBOE
| OCUL | Real-time | |
|
Tradegate
| 0OT | Real-time | |
|
Boerse Muenchen
| 0OT | Real-time | |
|
Deutsche Boerse AG
| 0OT | Delayed | |
|
Börse Stuttgart
| 0OT | Delayed | |
|
Berne S.E.
| 0OT | End-of-day quote |
Last Transcript: Ocular Therapeutix, Inc.
| 1 day | -3.91% | ||
| 1 week | -27.46% | ||
| Current month | -8.74% | ||
| 1 month | -35.78% | ||
| 3 months | -27.39% | ||
| 6 months | -17.55% | ||
| Current year | -42.34% |
| 1 week | 6.98 |  | 9.38 |
| 1 month | 6.98 | | 11.48 |
| Current year | 6.23 | | 13.03 |
| 1 year | 6.23 | | 16.44 |
| 3 years | 2 | | 16.44 |
| 5 years | 2 | | 16.44 |
| 10 years | 2 | | 24.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pravin Dugel
CEO | Chief Executive Officer | 62 | 15/04/2024 |
Jason Robins
DFI | Director of Finance/CFO | 50 | 20/01/2026 |
Nadia Waheed
CTO | Chief Tech/Sci/R&D Officer | 49 | 20/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Charles Warden
CHM | Chairman | 57 | 01/07/2019 |
| Director/Board Member | 78 | 05/11/2012 | |
Leslie Williams
BRD | Director/Board Member | 66 | 20/03/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Sell | Chief Operating Officer | -1,099 | 0.0005% | ||
| 25/08/26 | Don | Chief Executive Officer | -1,00,184 | 0.0473% | ||
| 24/08/26 | Sell | Executive/Senior Manager | -3,035 | 0.0014% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.98% | -27.46% | -36.71% | +137.29% | 160.1Cr | |
| -0.50% | -3.34% | +39.53% | +112.52% | 1,02500Cr | |
| -1.28% | -5.80% | +37.37% | +64.67% | 62TCr | |
| +0.83% | -0.80% | +10.85% | +76.87% | 46TCr | |
| -0.30% | -3.58% | +60.26% | +39.88% | 35TCr | |
| -0.95% | -4.05% | +21.60% | +39.37% | 34TCr | |
| -1.46% | -2.89% | +11.84% | +24.60% | 27TCr | |
| -1.35% | -5.43% | -4.69% | +8.40% | 25TCr | |
| -0.81% | -2.60% | +35.78% | +51.63% | 22TCr | |
| -2.19% | -4.40% | +30.51% | +94.73% | 18TCr | |
| Average | -1.22% | -4.28% | +20.63% | +65.00% | 37.2TCr | |
| Weighted average by Cap. | -0.74% | -2.12% | +30.35% | +68.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.29Cr 4.7Cr 4.39Cr 4Cr 7.54Cr 508.81Cr 7.62Cr 53Cr 21Cr 260.11Cr 20Cr 19Cr 834.78Cr | 10Cr 9.11Cr 8.5Cr 7.75Cr 15Cr 985.14Cr 15Cr 102.84Cr 40Cr 503.62Cr 38Cr 38Cr 1.62TCr |
| Net income | -33Cr -30Cr -28Cr -25Cr -48Cr -3.21TCr -48Cr -335.49Cr -130Cr -1.64TCr -125.51Cr -122.79Cr -5.27TCr | -32Cr -29Cr -27Cr -25Cr -46Cr -3.12TCr -47Cr -325.56Cr -126.15Cr -1.59TCr -121.8Cr -119.15Cr -5.12TCr |
| Net Debt | -38Cr -34Cr -31Cr -29Cr -54Cr -3.63TCr -54Cr -379.35Cr -147Cr -1.86TCr -141.92Cr -138.84Cr -5.96TCr | -6.6Cr -5.86Cr -5.47Cr -4.99Cr -9.41Cr -634.48Cr -9.5Cr -66Cr -26Cr -324.35Cr -25Cr -24Cr -1.04TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $7.005 | -3.91% | 29,84,956 |
| 01/26/01 | $7.290 | -4.95% | 45,14,297 |
| 30/26/30 | $7.670 | -2.54% | 45,68,574 |
| 29/26/29 | $7.870 | +2.81% | 52,86,714 |
| 28/26/28 | $7.655 | -20.67% | 1,54,42,389 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- OCUL Stock
Select your edition
All financial news and data tailored to specific country editions
